通常取引データ（自動更新なし）RVOL 0.4xDV $27,34420日平均DV $73,951?
52W high -10.0%52W low +32.7%Fwd PER 13.7xMarket cap $32MAvg volume 19K
Company Overview
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Earnings & Financials
Earnings actuals
| Period | EPS | Revenue | FCF |
|---|
| 2026 Q2 | -0.54 | $0 | -$2M |
| 2026 Q1 | -0.27 | $0 | -$3,019 |
| 2025 Q4 | -0.15 | $0 | -$1M |
| 2025 Q2 | -0.08 | $0 | -$120,430 |
| 2025 Q1 | -0.08 | $0 | -$217 |
| 2024 Q4 | -0.05 | $0 | -$243 |
| 2024 Q3 |
